A deliberate, public roadmap.
Cellindex is not a research tools company that might one day pivot to services. The CRO is the destination. The ELN is step one. We publish this because scientists building workflows around our products deserve to know where we are heading.
Cellindex formed. ELN prototypes shipped to the first partner labs. Core data model, audit trail architecture, and technology stack decided.
Cultures, passages, plates, reagents, protocols, and signed entries live for academic users. Free tier open. Active feedback loop with early adopters.
Industry tier: team collaboration, SSO, full electronic signatures, and the audit trail required for regulated environments.
Internal QMS with controlled SOPs, deviation handling, and CAPA. The procedural backbone that everything downstream depends on.
Third-party audit and certification of our quality processes. We don't skip steps.
Validated workflows and computer system validation for regulated pre-clinical and clinical work.
Cellindex begins offering end-to-end contract research for cell-based therapy development and assays — built on the quality infrastructure we have been assembling since day one.
Transparency is part of the product.
Labs considering Cellindex — especially those in regulated environments — need to know where we are going, not just where we are. This roadmap is a commitment, not a marketing exercise.
We update it when things change. If a milestone slips, we will say so and explain why. The sequence matters as much as the destination.
Every step must be earned.
We do not skip the QMS to reach GCP. We do not skip GCP to reach the CRO. Each milestone is a prerequisite for the next — not a bureaucratic formality, but the actual mechanism by which quality accumulates.
The foundation. Quality records from day one.
Controlled procedures. Deviation handling. CAPA.
Validated systems. Regulated-environment ready.
End-to-end contract research, earned not assumed.
Planning ahead?
Academic lab, industry partner, or just curious — we're happy to talk.